Additional file 3 of Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors

Pei Zhang, Yang Du, Hua Bai, Zhijie Wang, Jianchun Duan, Xin Wang, Jia Zhong, Rui Wan, Jiachen Xu, Xiran He, Di Wang, Kailun Fei, Ruofei Yu, Jie Tian & Jie Wang
Additional file 3. Tucidinostat plus checkpoint blockade induces improved therapeutic efficacy. a Schema of the experiment. For bioluminescence imaging (BLI) in vivo, mouse 4T1-luc (5 × 105 cells) were engrafted into the flank of BALB/c mice. When established tumors were palpable 7 days after tumor cells inoculation, mice were treated with vehicle (DMSO, n=7), tucidinostat (25 mg/kg, gavage, daily, n=7), aPD-L1 (200 μg, i.p. injection, once every 3 days, n=7), or combination (n=7). Tumors volume...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.